title: Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
abstract: The epidermal growth factor receptor (EGFR) inhibitor class of agents have been reported to cause multiple cutaneous adverse events. These drug eruptions are thought by some to indicate a good prognosis. The authors report of a case of a psoriasiform scalp eruption simultaneously occurring with an acneiform or follicular rash in a single patient. To present knowledge, this is the first report of a psoriasiform eruption triggered by erlotinib. In addition, this case report demonstrates 2 completely distinct cutaneous morphologies occurring simultaneously with erlotinib therapy in a single patient.
authors.affiliation: Rush University Medical Center, Chicago, IL 60612, USA. tracy_campbell@rush.edu
authors.forename: Tracy M
authors.initials: TM
authors.lastname: Campbell
authors.forename: Clarence W
authors.initials: CW
authors.lastname: Brown
mesh_terms: D017486:Acneiform Eruptions / Q000139:chemically induced; D000368:Aged; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D000069347:Erlotinib Hydrochloride; D005499:Folliculitis / Q000139:chemically induced; D006801:Humans; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011565:Psoriasis / Q000139:chemically induced; D011799:Quinazolines / Q000009:adverse effects*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride